Biohit Oyj Decisions of the Annual General Meeting, June 6, 2024 at 9.30 am local time (EET)
The Annual General Meeting (AGM) of Biohit Oyj held on Wednesday June 5, 2024 approved the financial statements for the financial year 2023. AGM decided to discharge the members of the Board of Directors and the President and CEO from liability for the financial year 2023. AGM decided to approve the Remuneration Report of the company's Governing Bodies and Remuneration Policy presented to the AGM; the decision is advisory.
Distribution of dividends
The AGM resolved in accordance with the proposal of the Board of Directors that no dividend is paid for the financial period ended on December 31, 2023.
Members of the Board of Directors
The AGM resolved that five (5) members are elected to the Board of Directors and that CEO Liu Feng, CEO Kalle Härkönen, Ph.D. Lea Paloheimo, LL.D, Lic (BA) Vesa Silaskivi and professor Osmo Suovaniemi are elected as members of the Board of Directors until the end of the next AGM.
Additionally, the AGM resolved that the Chairman of the Board of Directors is paid a meeting fee of EUR 2,500 and the other members of the Board of Directors are paid a meeting fee of EUR 2,000.
Election of the Auditor and remuneration for the Auditor
The AGM elected authorized public accountants PricewaterhouseCoopers Oy as the company's auditor until the end of the next AGM and that the auditor is paid remuneration according to invoice approved by the company.
All decisions of the AGM were made unanimously. The minutes of the AGM will be available for review by shareholders by Monday June 10, 2024 on the company's website (www.biohithealthcare.com/investors) and at the corporate headquarters of Biohit Oyj, located at Laippatie 1, 00880 Helsinki.
Additional information:
CEO Jussi Hahtela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is "Innovating for Health" - we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com
